Free Cash Flow to The Firm (FCFF)
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).
1, 2 See details »
An analysis of the financial performance from 2019 to 2023 reveals a generally positive trajectory in cash generation, characterized by a significant dip in 2022 followed by a strong recovery in 2023.
- Net Cash Provided by Operating Activities
- Operating cash flow demonstrated an overall upward trend, growing from 1,795 million US$ in 2019 to a peak of 2,353 million US$ in 2023. Growth was consistent through 2021, reaching 2,213 million US$, before experiencing a contraction of approximately 13.6% in 2022 to 1,912 million US$. The subsequent rebound in 2023 represents the highest operational cash generation within the observed five-year period.
- Free Cash Flow to the Firm (FCFF)
- FCFF followed a pattern closely aligned with operating cash flows, increasing from 1,552 million US$ in 2019 to 1,959 million US$ by 2021. A more pronounced decline occurred in 2022, where FCFF dropped to 1,535 million US$, a decrease of approximately 21.6% from the previous year. By 2023, FCFF recovered to 1,878 million US$, although this remains below the 2021 peak.
- Cash Conversion and Capital Intensity
- The variance between operating cash flow and FCFF indicates a trend of increasing capital expenditure or investment requirements. In 2019, the gap was 243 million US$, whereas by 2023, this difference expanded to 475 million US$. The conversion rate of operating cash to FCFF declined from a high of approximately 89% in 2020 to 80% in 2023, suggesting a shift toward higher capital intensity to support operations or growth.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
How can I help you?
Interest Paid, Net of Tax
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).
2 2023 Calculation
Cash paid during the period for interest, net of capitalized interest, tax = Cash paid during the period for interest, net of capitalized interest × EITR
= 295 × 20.30% = 60
3 2023 Calculation
Capitalized interest expense, tax = Capitalized interest expense × EITR
= 27 × 20.30% = 5
The financial data reveals a general upward trajectory in both the effective tax burden and the costs associated with interest expenditures over the five-year period from 2019 to 2023. While cash interest payments exhibited some volatility, the capitalized interest expenses showed a consistent linear increase.
- Effective Income Tax Rate Trends
- The effective income tax rate experienced a steady increase from 16.70% in 2019 to a peak of 20.50% in 2022, before settling slightly at 20.30% in 2023. This represents an overall increase of 360 basis points over the analyzed period, indicating a higher proportional tax obligation on taxable income.
- Net Cash Interest Outflows
- Cash paid for interest, net of capitalized interest and tax, remained relatively stable between 2019 and 2021, fluctuating between 206 million and 211 million US dollars. A contraction occurred in 2022, with payments dropping to 192 million US dollars, followed by a significant increase to 235 million US dollars in 2023. This final increase marks the highest cash interest outflow in the recorded period.
- Capitalized Interest Growth
- Capitalized interest expense, net of tax, demonstrated a consistent year-over-year increase throughout the entire period. Starting at 11 million US dollars in 2019, the figure grew annually to reach 22 million US dollars by 2023. This 100% increase suggests an expansion in the financing of long-term assets or infrastructure projects that qualify for interest capitalization.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
How can I help you?
Enterprise Value to FCFF Ratio, Current
| Selected Financial Data (US$ in millions) | |
| Enterprise value (EV) | 80,835) |
| Free cash flow to the firm (FCFF) | 1,878) |
| Valuation Ratio | |
| EV/FCFF | 43.05 |
| Benchmarks | |
| EV/FCFF, Competitors1 | |
| AbbVie Inc. | 26.68 |
| Amgen Inc. | 24.87 |
| Bristol-Myers Squibb Co. | 11.04 |
| Danaher Corp. | 29.47 |
| Eli Lilly & Co. | 117.21 |
| Gilead Sciences Inc. | 18.99 |
| Johnson & Johnson | 30.24 |
| Merck & Co. Inc. | 28.98 |
| Pfizer Inc. | 18.47 |
| Regeneron Pharmaceuticals Inc. | 18.36 |
| Thermo Fisher Scientific Inc. | 34.67 |
| Vertex Pharmaceuticals Inc. | 37.90 |
| EV/FCFF, Sector | |
| Pharmaceuticals, Biotechnology & Life Sciences | 35.64 |
| EV/FCFF, Industry | |
| Health Care | 30.72 |
Based on: 10-K (reporting date: 2023-12-31).
1 Click competitor name to see calculations.
If the company EV/FCFF is lower then the EV/FCFF of benchmark then company is relatively undervalued.
Otherwise, if the company EV/FCFF is higher then the EV/FCFF of benchmark then company is relatively overvalued.
Enterprise Value to FCFF Ratio, Historical
| Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Enterprise value (EV)1 | 88,543) | 83,977) | 96,445) | 82,629) | 73,350) | |
| Free cash flow to the firm (FCFF)2 | 1,878) | 1,535) | 1,959) | 1,898) | 1,552) | |
| Valuation Ratio | ||||||
| EV/FCFF3 | 47.16 | 54.71 | 49.22 | 43.54 | 47.27 | |
| Benchmarks | ||||||
| EV/FCFF, Competitors4 | ||||||
| AbbVie Inc. | 14.89 | 12.15 | 13.18 | — | — | |
| Amgen Inc. | 22.22 | 16.01 | 15.82 | — | — | |
| Bristol-Myers Squibb Co. | 9.14 | 13.87 | 10.52 | — | — | |
| Danaher Corp. | 36.34 | 25.74 | 28.25 | — | — | |
| Eli Lilly & Co. | 655.43 | 59.17 | 38.39 | — | — | |
| Gilead Sciences Inc. | 13.41 | 13.58 | 8.42 | — | — | |
| Johnson & Johnson | 19.30 | 23.80 | 21.25 | — | — | |
| Merck & Co. Inc. | 37.84 | 19.09 | 23.27 | — | — | |
| Pfizer Inc. | 32.24 | 9.15 | 8.40 | — | — | |
| Regeneron Pharmaceuticals Inc. | 25.33 | 23.31 | 9.81 | — | — | |
| Thermo Fisher Scientific Inc. | 28.85 | 31.61 | 33.14 | — | — | |
| Vertex Pharmaceuticals Inc. | 29.45 | 16.68 | 22.47 | — | — | |
| EV/FCFF, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | 27.29 | 18.08 | 16.12 | — | — | |
| EV/FCFF, Industry | ||||||
| Health Care | 25.98 | 18.66 | 17.80 | — | — | |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).
3 2023 Calculation
EV/FCFF = EV ÷ FCFF
= 88,543 ÷ 1,878 = 47.16
4 Click competitor name to see calculations.
The financial performance from 2019 to 2023 is characterized by fluctuations in both enterprise value and the generation of free cash flow to the firm, resulting in a volatile valuation multiple. Enterprise value peaked in 2021 at 96,445 million US$ before experiencing a correction in 2022 and a moderate recovery to 88,543 million US$ by the end of 2023.
- Free Cash Flow to the Firm (FCFF) Trends
- FCFF exhibited a general upward trajectory from 2019 to 2021, rising from 1,552 million US$ to 1,959 million US$. A notable contraction occurred in 2022, where FCFF dropped to 1,535 million US$, representing the lowest level in the analyzed period. However, a recovery was observed in 2023, with FCFF returning to 1,878 million US$.
- EV/FCFF Ratio Analysis
- The EV/FCFF ratio remained elevated throughout the period, fluctuating between 43.54 and 54.71. The ratio reached its peak in 2022 at 54.71, which coincided with the period of lowest FCFF and a simultaneous decline in enterprise value. This indicates that the decline in cash flow generation outpaced the compression of the enterprise value during that fiscal year.
- Valuation Convergence
- By December 31, 2023, the EV/FCFF ratio normalized to 47.16, nearly identical to the 47.27 ratio recorded in 2019. This convergence suggests that despite the intermediate volatility in both cash flows and market valuation, the relationship between the enterprise value and the firm's ability to generate free cash flow has returned to its baseline level over the five-year cycle.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
How can I help you?